PaTH Forward: A randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism.
Aliya A KhanLars RejnmarkMishaela RubinPeter SchwarzTamara VokesBart ClarkeIntekhab AhmedLorenz HofbauerClaudio MarcocciUberto PagottoAndrea PalermoErik EriksenMeryl BrodDenka MarkovaAlden SmithSusanne PihlSanchita MouryaDavid B KarpfAimee D ShuPublished in: The Journal of clinical endocrinology and metabolism (2021)
TransCon PTH enabled independence from oral active vitamin D and reduced Ca supplements (≤ 500 mg/day) for most subjects, achieving normal sCa, sP, uCa, CaxP, and demonstrating improved health-related quality of life. These results support TransCon PTH as a potential hormone replacement therapy for adults with hypoparathyroidism.